Literature DB >> 32797629

No temporal association between human coronavirus and Kawasaki disease: National data from South Korea.

Seung-Ah Choe1, Hyo Soon An2, Young June Choe3.   

Abstract

Entities:  

Keywords:  coronavirus; epidemiology; seasonal incidence

Mesh:

Year:  2020        PMID: 32797629      PMCID: PMC7436667          DOI: 10.1002/jmv.26435

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   20.693


× No keyword cloud information.
Despite advances in our understanding of the pathogenesis of Kawasaki disease, its association with respiratory viruses remains unclear. Previous studies have suggested a possible association between human coronavirus (HCoV) NL63 and 229E with Kawasaki disease, however none were confirmed to be causal. , Amid coronavirus disease 2019 (COVID‐19) pandemic and its hypothesized association with Kawasaki‐like illness, it is important to understand the temporal association between Kawasaki disease and the HCoVs. With one of the highest incidence rate of Kawasaki disease, the large sample size data from South Korea, would provide opportunity to investigate the possible association between HCoVs and Kawasaki disease. We used national representable data on respiratory virus activity from the Korea Influenza and Respiratory Viruses Surveillance System (KINRESS), the sentinel surveillance in operation since 2009, to extract monthly occurrence of HCoV. The KINRESS collects respiratory specimens from patients with acute respiratory illness visiting 52 medical facilities across the country. HCoVs are tested using reverse transcription‐polymerase chain reaction. We calculated the mean monthly proportion of HCoV to assess the relative prevalence among all respiratory specimens. We accessed the Health Insurance Review and Assessment Service database, a single‐payer that covers more than 99% of the residents. The monthly number of patients diagnosed with Kawasaki disease, coded with ICD‐10‐CM with M303, was retrieved from January 2016 to October 2019. The monthly new incident of Kawasaki disease was merged with the monthly proportion of HCoV. Linear regression analysis was done to assess differences in the log‐transformed incidence of Kawasaki disease across season and year, and time series were plotted using distributed lag linear models (DLNMs). We estimated the overall cumulative effect of a 10‐unit increase in the proportion of HCoV infection over 1 month of lag on the frequency of Kawasaki disease by calculating cumulative relative risk. This study was approved by CHA University Institutional Review Board (GCI 2020‐06‐006). There was no active patient and public involvement in this study. Between January 2016 to October 2019, the seasonality of HCoV peaked in December and January, with an average proportion of 2.9% (Figure 1). During the observed period, the annual incidence of Kawasaki disease ranged between 293 and 397 per 100 000 population and occurred least frequently in fall (September‐November, regression coefficient = −0.23, P = .005). In DLNM, cumulative association of Kawasaki disease per 10% increase in the proportion of HCoV infection over 1 month lag with coronavirus was 0.50 (95% confidence interval: 0.16, 1.53), suggesting that seasonal variation in the frequencies of HCoV was not significantly associated with the change in the incidence of Kawasaki disease in South Korea.
Figure 1

Monthly frequency of Kawasaki disease patients and the proportion of coronavirus detected in the national surveillance samples, South Korea, 2016 to 2019. Red lines are the monthly incidence of Kawasaki disease. Blue lines are the monthly proportion of coronavirus detected by the National Surveillance System

Monthly frequency of Kawasaki disease patients and the proportion of coronavirus detected in the national surveillance samples, South Korea, 2016 to 2019. Red lines are the monthly incidence of Kawasaki disease. Blue lines are the monthly proportion of coronavirus detected by the National Surveillance System Temporal association of various respiratory viruses and Kawasaki disease has been noted previously, however association remains unclear. Our finding demonstrated no temporal association between HCoV and Kawasaki disease at the national level in South Korea. The concerns about the risk of inducing Kawasaki disease by HCoV do not, therefore, seem justified by our data. We found that the annual peak incidence of HCoV not coincided with the peak incidence of Kawasaki disease during distinct seasonal periods. There was no significant seasonal overlap in the peak incidence of HCoVs although this association was at the population level not at the individual patient level. This leads us to question whether the detection of an HCoV in a particular patient was associated with the occurrence of Kawasaki disease in the same patient. Clearly, more studies need to be done to elucidate their association at the individual level. There are several limitations to this study. First, given the study is ecological in nature, aggregated de‐identified laboratory data (individual HCoVs) and season from nationally notifiable disease surveillance system and insurance claim data that did not allow us to determine if one virus was detected in any particular person. Second, potential variation in frequency and quality of obtaining respiratory specimens may play a role in this finding causing a chance for misclassification bias. Third, other external factors such as environmental factors and temporal trends of different HCoVs were not accounted into the study design. However, our study method permitted us to study a relatively large number of cases at the national level to test our hypothesis. To our knowledge, this is the first study to summarize and appraise the association between HCoVs with Kawasaki disease at a national level while controlling the seasonality factor. We observed a no association between HCoVs and Kawasaki disease, which demonstrates no potential epidemiological linkage to explain the pathogenesis of Kawasaki disease. Amid COVID‐19 pandemic, the relation between the HCoV and Kawasaki disease is of special interest, owing to the clinical implication in children. To counteract these concerns, several places have started surveillance to detect cases of multisystem inflammatory disease in children (MIS‐C). The results are awaited, but cases of MIS‐C have been reported elsewhere. It is important to continue active and passive surveillance to monitor the adverse health outcomes in children with COVID‐19 to assess the pathogenesis and clinical severity of severe acute respiratory syndrome coronavirus 2 in children exhibiting Kawasaki‐like illness or multisystem inflammatory syndromes.

CONFLICT OF INTERESTS

The authors declare that there are no conflict of interests.

AUTHOR CONTRIBUTIONS

YJC conceptualized and designed the study, drafted the initial manuscript, and reviewed and revised the manuscript. S‐AC designed the epidemiologic investigation protocols, collected data, carried out the initial analyses, and reviewed and revised the manuscript. HSA conceptualized and designed the study, coordinated, and critically reviewed the manuscript. YJC conceptualized and designed the study and oversaw the study process.
  8 in total

1.  Distributed Lag Linear and Non-Linear Models in R: The Package dlnm.

Authors:  Antonio Gasparrini
Journal:  J Stat Softw       Date:  2011-07       Impact factor: 6.440

2.  Reality of Kawasaki disease epidemiology.

Authors:  Gi Beom Kim
Journal:  Korean J Pediatr       Date:  2019-07-09

3.  Possible involvement of infection with human coronavirus 229E, but not NL63, in Kawasaki disease.

Authors:  Kazuya Shirato; Yoshio Imada; Miyuki Kawase; Keiko Nakagaki; Shutoku Matsuyama; Fumihiro Taguchi
Journal:  J Med Virol       Date:  2014-04-24       Impact factor: 2.327

4.  Association between a novel human coronavirus and Kawasaki disease.

Authors:  Frank Esper; Eugene D Shapiro; Carla Weibel; David Ferguson; Marie L Landry; Jeffrey S Kahn
Journal:  J Infect Dis       Date:  2005-01-14       Impact factor: 5.226

5.  An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study.

Authors:  Lucio Verdoni; Angelo Mazza; Annalisa Gervasoni; Laura Martelli; Maurizio Ruggeri; Matteo Ciuffreda; Ezio Bonanomi; Lorenzo D'Antiga
Journal:  Lancet       Date:  2020-05-13       Impact factor: 79.321

6.  Viral infections associated with Kawasaki disease.

Authors:  Luan-Yin Chang; Chun-Yi Lu; Pei-Lan Shao; Ping-Ing Lee; Ming-Tai Lin; Tsui-Yien Fan; Ai-Ling Cheng; Wan-Ling Lee; Jen-Jan Hu; Shu-Jen Yeh; Chien-Chih Chang; Bor-Luen Chiang; Mei-Hwan Wu; Li-Min Huang
Journal:  J Formos Med Assoc       Date:  2014-02-01       Impact factor: 3.282

7.  Nation-wide surveillance of human acute respiratory virus infections between 2013 and 2015 in Korea.

Authors:  Jeong-Min Kim; Hee-Dong Jung; Hyang-Min Cheong; Anna Lee; Nam-Joo Lee; Hyuk Chu; Joo-Yeon Lee; Sung Soon Kim; Jang-Hoon Choi
Journal:  J Med Virol       Date:  2018-03-25       Impact factor: 2.327

8.  No temporal association between human coronavirus and Kawasaki disease: National data from South Korea.

Authors:  Seung-Ah Choe; Hyo Soon An; Young June Choe
Journal:  J Med Virol       Date:  2020-08-21       Impact factor: 20.693

  8 in total
  3 in total

Review 1.  Immune pathogenesis of COVID-19-related multisystem inflammatory syndrome in children.

Authors:  Anne H Rowley; Stanford T Shulman; Moshe Arditi
Journal:  J Clin Invest       Date:  2020-11-02       Impact factor: 14.808

2.  Incidence of Kawasaki disease before and during the COVID-19 pandemic: a retrospective cohort study in Japan.

Authors:  Kyohei Iio; Kousaku Matsubara; Chisato Miyakoshi; Kunitaka Ota; Rika Yamaoka; Junji Eguchi; Osamu Matsumura; Takahiro Okutani; Ikuyo Ueda; Masahiro Nishiyama
Journal:  BMJ Paediatr Open       Date:  2021-04-02

3.  No temporal association between human coronavirus and Kawasaki disease: National data from South Korea.

Authors:  Seung-Ah Choe; Hyo Soon An; Young June Choe
Journal:  J Med Virol       Date:  2020-08-21       Impact factor: 20.693

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.